TOP TEN perturbations for 1553534_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553534_at
Selected probe(set): 1553534_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553534_at (1553534_at) across 6672 perturbations tested by GENEVESTIGATOR:

keratinocyte differentiation study 2 (ZNF750 siRNA) / keratinocyte differentiation study 2

Relative Expression (log2-ratio):-4.420123
Number of Samples:2 / 2
Experimental keratinocyte differentiation study 2 (ZNF750 siRNA)
ZNF750 (zinc finger protein 750) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. ZNF750 depletion was done using siRNAs: ZNF750i(A): CCACCAGAGTTTCCACATA, ZNF750i(B): GCCGATTCCTTACGGATTT. Differentiation was induced at 100% confluency.
Control keratinocyte differentiation study 2
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-3.0203524
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):2.9509544
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):2.5088463
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

cutaneous T-cell lymphoma study 1 (tumor phase) / cutaneous T-cell lymphoma study 1 (plaque phase)

Relative Expression (log2-ratio):-2.0832577
Number of Samples:4 / 7
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.

actinic keratosis study 1 / skin squamous cell carcinoma study 1

Relative Expression (log2-ratio):1.8770905
Number of Samples:10 / 30
Experimental actinic keratosis study 1
Skin biopsy from patients with actinic keratosis (AK). Biopsies of skin tissue from different location were snap frozen with liquid nitrogen upon excision during surgery and stored at -80°C. RNA was extracted from fresh frozen tissue specimens by laser capture microdissection. The AK samples included both immunocompetent and immunosuppressed patients (organ transplant recipients (OTRs) or patient with chronic lymphocytic leukemia) and were estimated to be a minimum 90% enrichment for dysplastic cells.
Control skin squamous cell carcinoma study 1
Primary tumor tissue sample from patients with cutaneous squamous cell carcinoma (cuSCC). Biopsies of tumor tissue from different location were snap frozen with liquid nitrogen upon excision during surgery and stored at -80°C. RNA was extracted from fresh frozen tissue specimens by laser capture microdissection. The cSCC samples included a range of histological diagnoses (well differentiated through to poorly differentiated) from both immunocompetent and immunosuppressed patients (organ transplant recipients (OTRs) or patient with chronic lymphocytic leukemia) and were estimated to be a minimum 90% enrichment for tumor.

engineered skin substitute study 2 (late) / engineered skin substitute study 1 (late)

Relative Expression (log2-ratio):-1.7328577
Number of Samples:5 / 3
Experimental engineered skin substitute study 2 (late)
Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; placebo; 43d)

Relative Expression (log2-ratio):-1.7180338
Number of Samples:8 / 4
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 43d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with placebo.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-1.6732006
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-1.6713428
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.